10 May 2024
Chiesi Farmaceutici S.p.A., an international, research-focused biopharmaceutical group, and Gossamer Bio, a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib.